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Forced swimming testAgmatine has been recently emerged as a novel candidate to assist the conventional pharmacotherapy of depres-
sion. The acute restraint stress (ARS) is anunavoidable stress situation thatmay cause depressive-like behavior in
rodents. In this study, we investigated the potential antidepressant-like effect of agmatine (10 mg/kg, adminis-
tered acutely by oral route) in the forced swimming test (FST) innon-stressedmice, aswell as its ability to abolish
the depressive-like behavior and hippocampal antioxidant imbalance induced by ARS. Agmatine reduced the im-
mobility time in the mouse FST (1–100 mg/kg) in non-stressed mice. ARS caused an increase in the immobility
time in the FST, indicative of a depressive-like behavior, as well as hippocampal lipid peroxidation, and an in-
crease in the activity of hippocampal superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione
reductase (GR) activities, reduced catalase (CAT) activity and increased SOD/CAT ratio, an index of pro-oxidative
conditions. Agmatine was effective to abolish the depressive-like behavior induced by ARS and to prevent the
ARS-induced lipid peroxidation and changes in SOD, GR and CAT activities and in SOD/CAT activity ratio. Hippo-
campal levels of reduced glutathione (GSH) were not altered by any experimental condition. In conclusion, the
present study shows that agmatinewas able to abrogate the ARS-induced depressive-like behavior and the asso-
ciated redox hippocampal imbalance observed in stressed restraint mice, suggesting that its antidepressant-like
effect may be dependent on its ability to maintain the pro-/anti-oxidative homeostasis in the hippocampus.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The relationship between onset of a major depressive episode and
prior stressful life events has been extensively reported (Hammen
et al., 2009; Kessler, 1997; Mazure, 1998). Abnormalities of the hypo-
thalamic pituitary adrenal (HPA) axis have been shown to play a critical
role in development of depressive symptoms, persistence of symptoms,
and recurrence of depression (Gold et al., 1988; Morris et al., 2012;
Plotsky et al., 1998). The progressive HPA abnormalities caused by trau-
matic stress or chronic stress not only trigger behaviors and emotions
related to depression and anxiety, but also might result in prolonged
cortisol hypersecretion that can account for neuronal death ande restraint stress; CAT, catalase;
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ghts reserved.hippocampal atrophy observed in depressed individuals (Lee et al.,
2002; McKinnon et al., 2009).
The neurotoxic effects of glucocorticoids induced by stress could
be partly explained by the inﬂammatory and neurodegenerative
hypothesis of depression, which postulates that oxidative and
nitrosative stresses contribute to neurodegenerative processes in
depression (Anisman et al., 2002; Lang and Borgwardt, 2013; Maes
et al., 2009, 2012). It is well recognized that the brain tissue is partic-
ularly vulnerable to oxidative damage, compared with other organs,
due to its relatively high content of iron and peroxidizable fatty
acids, besides its limited antioxidant capacity (Floyd, 1999; Herbert
et al., 1994). There is now ample evidence that ROS produced in the
brain are deleterious to neurons since they may overwhelm the brain
antioxidant defenses, thereby causing oxidative damage to lipids, pro-
teins and DNA, events that play a key role in neuronal cell death
(Forlenza and Miller, 2006; Lang and Borgwardt, 2013; Sarandol et al.,
2007).
Several studies have demonstrated that different kinds of stress,
including restraint stress, cause an impairment in the antioxidant
status in the brain (de Balk et al., 2010; Enache et al., 2008; García-
Fernández et al., 2012; Kumar and Goyal, 2008), which could be
prevented by antidepressant drugs from distinct classes, namely
imipramine and clomipramine (tricyclic antidepressants, TCAs), ﬂu-
oxetine and venlafaxine (selective serotonin reuptake inhibitors,
Fig. 1.Diagramof all experimental schedules. Agmatine at dose of 10 mg/kg (p.o.)was ad-
ministered 1 h before the ARS procedure. The animals were submitted to immobilization
for a period of 7 h. 40 min post-release from their enclosure, independent group of ani-
mals was submitted to the open-ﬁeld, or FST, or hippocampi tissue was rapidly dissected
and prepared for biochemical analysis.
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Kumar et al., 2009, 2010; Zaﬁr and Banu, 2007; Zaﬁr et al., 2009).
However, most of the clinically available antidepressants have only
marginal efﬁcacy compared with placebo (Kirsch, 2009). Therefore,
there is a clear need for novel drugs or augmentation therapies to in-
crease the efﬁcacy of antidepressants.
Also known as “decarboxylated arginine”, agmatine is an endoge-
nous metabolite situated between the critical pathways of nitric oxide
production, polyamine metabolism, and the urea cycle (Reis and
Regunathan, 2000). Agmatine has been proposed as a neuromodulator
in the central nervous system, considering that it : a) is stored in a
large number of neurons with selective distribution in the brain
(Otake et al., 1998); b) is released from synaptosomes in a Ca2+-
dependent manner (Sastre et al., 1997); c) is enzymatically degraded
by agmatinase in synaptosomes (Tabor and Tabor, 1984); d) is
inactivated by selective reuptake (Sastre et al., 1997); and e) has several
molecular targets in the brain, namely I1R, andα2-adrenergic receptors,
5HT3 receptors; inhibits membrane Ca(2+) channels, all isoforms of
nitric oxide synthase (NOS) in the brain, and blocks N-methyl-D-
aspartate (NMDA) receptors (Reis and Regunathan, 1998, 1999, 2000).
In addition, it is remarkable to note agmatine's ability to act as a
free radical scavenger protecting from oxidative stress-induced mi-
tochondrial swelling, membrane potential collapse, NF-κB transloca-
tion, and apoptosis (Arndt et al., 2009; Battaglia et al., 2010; Condello
et al., 2011). In addition, agmatine has been emerging as a putative
alternative therapeutic tool that could help the conventional phar-
macotherapy of depression. Previous studies by our group have
demonstrated that it is able to produce an antidepressant-like effect
in the mouse forced swimming test (FST) and in the tail suspension
test (TST), which was paralleled by modulation of monoaminergic
and opioid systems, NMDA receptors and the L-arginine–NO pathway
(Zomkowski et al., 2002, 2004, 2005). Of note, a recent study by
Shopsin (2013) showed a clinical antidepressant effect of agmatine in
depressed subjects. However, there is no study reporting the ability of
this neuromodulator to abolish depressive-like behavior induced by a
model that reproduces symptoms of depression accompanied by an ox-
idative imbalance. Therefore, the present study was aiming at investi-
gating the ability of agmatine to abrogate alterations in behavior and
in the hippocampal cellular redox status induced by acute restraint
stress (ARS).
2. Materials and methods
2.1. Animals
Female Swiss mice (3 months old, 40–45 g) were maintained at
constant room temperature (20–22 °C) with free access to water and
food, under a 12:12 h light:dark cycle (lights on at 07:00 h). The cages
were placed in the experimental room 24 h before the test for acclima-
tization. All manipulations were carried out between 9:00 and 17:00 h,
with each animal used only once. The procedures in this studywere per-
formed in accordance with the NIH Guide for the Care and Use of Labo-
ratory Animals and approved by the local Ethics Committee. All efforts
were made to minimize animal suffering and the number of animals
used in the experiments.
2.2. Drugs and treatment
Agmatine (Sigma Chemical Co., St. Louis, U.S.A.) was dissolved in
distilled water and was administered by oral route (p.o.) by gavage
at doses of 1–100 mg/kg. The dissolution of agmatine was freshly
done immediately before its administration. A control group re-
ceived distilled water as vehicle.
In the experiments designed to study the antidepressant-like ef-
fect of agmatine in the FST, the immobility time in the FST and the
locomotor activity in the open-ﬁeld were assessed in independentgroups of mice 60 min after an acute administration of agmatine by
gavage (1–100 mg/kg, p.o.). This experiment was carried out in order
to choose the dose of agmatine to be used in subsequent experiments
that investigated the ability of agmatine to abolish the depressive-like
behavior and hippocampal redox impairment induced by ARS.
In the ARS protocol, agmatine (10 mg/kg, p.o.)was administered 1 h
before the ARS. The animals were assigned to the following groups:
(a) unstressed/vehicle, (b) unstressed/agmatine, as the control groups;
(c) ARS/vehicle and (d) ARS/agmatine. Number of mice per group was
7–8. A diagram of all experimental schedules is given in Fig. 1.
2.3. Acute restraint stress procedure
After 1 h of the treatment, ARS procedurewas performed by ameth-
od described previously (Kumar and Goyal, 2008; Poleszak et al., 2006;
Zaﬁr et al., 2009) and standardized in our laboratory (Budni et al., 2013;
Moretti et al., 2013). The animals were maintained in their home cages
with free access to water and food in the period (1 h) that elapsed be-
tween the treatment and ARS procedure. The immobilization was
applied for a period of 7 h using an individual rodent restraint device
made of Plexiglas fenestrate. This restrained all physical movements
without causingpain. The animalswere deprived of food andwater dur-
ing the entire period of exposure to stress. The unstressed-groups were
treatedwith vehicle or agmatine andwere keptwithout food andwater
during the entire period of exposure to stress. Forty min after ARS, the
animalswere released from their enclosure, submitted to the behavioral
observations, and then to the neurochemical analysis.
2.4. Behavioral tests
2.4.1. Open-ﬁeld test
To assess the effects of agmatine on locomotor activity, mice were
evaluated in the open-ﬁeld paradigm as previously described by
Rodrigues et al. (1996). The number of squares crossed with all paws
(crossings) was counted in a 6 min session. The apparatus was cleaned
with a solution of 10% ethanol between tests in order to hide animal
clues.
2.4.2. Forced swimming test (FST)
Mice were individually forced to swim in an open cylindrical con-
tainer (diameter 10 cm, height 25 cm), containing 19 cm of water
(depth) at 25 ± 1 °C; the total amount of time each animal remained
immobile during a 6-min session was recorded (in seconds) as immo-
bility time, as described previously (Brocardo et al., 2008; Freitas et al.,
2010). Each mouse was judged to be immobile when it ceased strug-
gling and remained ﬂoating motionless in the water, making only
those movements necessary to keep its head above water. A decrease
in the duration of immobility is indicative of an antidepressant-like
effect (Porsolt et al., 1977).
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Considering that: a) the glutathione reductase (GR), glutathione
peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD)
are key endogenous antioxidant enzymes, which inhibit the formation
of ROS and/or promote the removal of free radicals and their precursors
(Bilici et al., 2001; Del Río et al., 1992; Floyd, 1999; Halliwell, 2007;
Kodydková et al., 2009); b) impairments in these detoxiﬁcation system
have been implicated in the etiology of depression (Anisman et al.,
2002; Lang and Borgwardt, 2013; Leonard and Maes, 2012; Maes
et al., 2009); c) lipid peroxidation is one of the major consequences of
free-radical-mediated injury to the brain (Halliwell and Gutteridge,
1999; Niki, 2012), and could be estimated by TBARS levels, the present
study assessed these neurochemical targets.
2.5.1. Tissue preparation
After the behavioral observations,micewere decapitated and hippo-
campus was rapidly dissected on ice and homogenized (1:10 w/v) in
HEPES buffer (20 mM, pH 7.0). The tissue homogenates were centri-
fuged at 16,000 ×g, at 4 °C for 20 min and the supernatants obtained
were used for the determination of enzymatic activities and for the
quantiﬁcation of the levels of glutathione (GSH) and thiobarbituric
acid reactive substances (TBARS). The protein content was quantiﬁed
according to themethod described by Lowry et al. (1951), using bovine
serum albumin as a standard.
2.5.2. Activity of antioxidant enzymes
Hippocampal glutathione reductase (GR) activity was measured
using an NADPH reduction assay following the protocol developed by
Carlberg and Mannervik (1985) using glutathione disulﬁde (GSSG)
as substrate. GR activity was monitored by decreases in NADPH ab-
sorbance at 340 nm at 37 °C in a TECAN Genios Microplate Reader
(Tecan Group Ltd., Männedorf, Switzerland). Results were based on
a molar extinction coefﬁcient for NADPH of 6.22 × 103 M−1 cm−1.
Hippocampal glutathione peroxidase (GPx) activity was measured
using an NADPH reduction assay following the technique of Wendel
(1981). Tissue supernatant (around 200 μg protein) was added to a re-
action mixture containing GSH, GR and NADPH in phosphate buffer
(pH 7.4). The reactionwas initiated by adding tert-butyl hydroperoxide,
and the absorbance decrease at 340 nm was recorded at 37 °C in a
TECAN Genios Microplate Reader (Tecan Group Ltd., Männedorf,
Switzerland). The activity in the absence of the samples was subtracted.
Results were based on a molar extinction coefﬁcient for NADPH of
6.22 × 103 M−1 cm−1. Both GR and GPx activities were expressed as
nmol NADPH oxidized/min/mg protein.
Catalase (CAT) activitywasmeasured by themethod of Aebi (1984).
The reaction was started by the addition of freshly prepared 30 mM
H2O2. The rate of H2O2 decomposition by catalase was measured spec-
trophotometrically at 240 nm and the enzyme activity was expressed
as μmol H2O2 consumed/min/mg protein.
Superoxide dismutase (SOD) activitywas assayed spectrophotomet-
rically as described byMisra and Fridovich (1972). The spectrophotom-
eter used for these assays was a TECAN Genios Microplate Reader
(Tecan Group Ltd., Männedorf, Switzerland). This method is based on
the capacity of SOD to inhibit autoxidation of adrenaline to adreno-
chrome. The color reaction was measured at 480 nm. One unit of
enzyme was deﬁned as the amount of enzyme required to inhibit the
rate of epinephrine autoxidation by 50%. The SOD enzymatic activity
was expressed as units (U)/mg protein.
2.5.3. Assessment of glutathione (GSH) content
GSH content was measured as nonprotein thiols (NPSH) according
to a method previously described (Ellman, 1959). Brieﬂy, after the
incubation, trichloroacetic acid 10% was added to the reactionmedium.
After centrifugation (5000 ×g at 4 °C for 10 min), the protein pellet
was discarded and free thiol groups were determined in the clearsupernatant (which was neutralized with 0.1 M NaOH). Absorbance
was read in 405 nm, using GSH as standard. The values are expressed
as nmol NPSH/mg protein.
2.5.4. Determination of thiobarbituric acid reactive substance (TBARS)
levels
TBARS levels were determined in the hippocampal homogenates
using the method described by Ohkawa et al. (1979), in which
malondialdehyde (MDA), an end-product of lipid peroxidation, re-
acts with thiobarbituric acid to form a colored complex.
The samples were incubated at 100 °C for 60 min in acid medium
containing 0.45% sodium dodecyl sulfate and 0.67% thiobarbituric acid.
After centrifugation, the reaction product was determined at 532 nm
using MDA as standard.
2.5.5. Statistical analysis
Comparisons between experimental and control groups were
performed by one-way or two-way ANOVA followed by Duncan's
multiple range test, when appropriate. Pearson's correlation analysis
was performed to investigate any possible relationship between behav-
ioral and neurochemical data. P b 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of an acute treatment with agmatine on the immobility time in
the FST and locomotor activity in the open-ﬁeld test
The results depicted in Fig. 2A show that agmatine given by oral
route decreased the immobility time in the FST, a behavioral proﬁle
characteristic of an antidepressant-like effect. One-way ANOVA
revealed a signiﬁcant effect of agmatine [F(3,24) = 8.72, P b 0.01].
Post hoc analysis indicated a signiﬁcant decrease in the immobility
time elicited by agmatine at doses of 1, 10 and 100 mg/kg (P b 0.01).
Fig. 2B shows that the administration of agmatine (dose range
1–100 mg/kg, p.o.) produced no effect in the locomotor activity in the
open-ﬁeld test [F(3,24) = 0.50, P = 0.69].
3.2. Agmatine abolished the depressive-like behavior induced by ARS
Fig. 3A shows that ARS caused a signiﬁcant increase in the immobil-
ity time, which is in agreementwith its ability to induce depressive-like
behavior. The acute administration of agmatine (10 mg/kg, p.o.) was
able to prevent the depressive-like behavior induced by ARS in the
FST. Agmatine administration, in control mice, also signiﬁcantly de-
creased the immobility time in the FST, as compared to unstressed
mice treated with vehicle. A two-way ANOVA revealed signiﬁcant
effects of ARS [F(1,28) = 3.92, P b 0.05], treatment [F(1,28) = 49.06,
P b 0.01] and ARS × treatment interaction [F(1,28) = 6.84, P b 0.01].
Post hoc analyses indicated that agmatine treatment to stressed mice
prevented the depressive-like behavior caused by ARS (P b 0.01).
Fig. 3B shows that the administration of agmatine produced no effect
in the open-ﬁeld test, indicating that a locomotor effect does not ac-
count for the antidepressant-like effect observed in the FST. The two-
way ANOVA revealed no signiﬁcant differences of ARS [F(1,28) =
0.10, P = 0.75], treatment [F(1,28) = 0.49, P = 0.48], and ARS ×
treatment interaction [F(1,28) = 0.002, P = 0.96].
3.3. Agmatine abolished the ARS-induced oxidative imbalance
The results depicted in Fig. 4 illustrate that ARS signiﬁcantly
increased the hippocampal levels of TBARS (an indicative of lipid
peroxidation) and that this event was signiﬁcantly blocked by
agmatine (10 mg/kg, p.o.) treatment; however no changes were ob-
served in the unstressed animals. The two-way ANOVA revealed signiﬁ-
cant differences of ARS [F(1,28) = 4.34, P b 0.05], treatment [F(1,28) =
6.10, P b 0.01] and ARS × treatment interaction [F(1,28) = 7.84,
Fig. 2. Effect of repeated acute administration by oral route (p.o.) of agmatine (dose range 1–100 mg/kg, p.o.) in the FST (panel A) and open-ﬁeld test (panel B). Each column represents the
mean + S.E.M. (n = 7–8). Statistical analysis was performed by one-way ANOVA, followed by Duncan's test. **P b 0.01 as compared with the vehicle-treated group (C).
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the increase in hippocampal TBARS levels caused by ARS (P b 0.01).
Fig. 5 shows that neither ARS nor agmatine treatment altered hippo-
campal GSH (the most important non-enzymatic endogenous antioxi-
dant) levels. A two-way ANOVA revealed no signiﬁcant differences of
ARS [F(1,28) = 1.91, P = 0.18], treatment [F(1,28) = 0.20, P = 0.66]
and ARS × treatment interaction [F(1,28) = 0.38, P = 0.54] for GSH
levels.
As depicted in Fig. 6A, ARS caused an increase on SOD (a class of en-
zymes that catalyzes the reduction of superoxide to hydrogen peroxide)
activity and this effect was abrogated by agmatine (10 mg/kg, p.o.)
treatment, however no changes were observed in the unstressed ani-
mals. The two-way ANOVA revealed signiﬁcant differences of ARS
[F(1,28) = 8.64, P b 0.01], treatment [F(1,28) = 15.84, P b 0.01] and
ARS × treatment interaction [F(1,28) = 4.97, P b 0.05]. Also, stressed
mice presented a decreased CAT (a relevant endogenous antioxidant
enzyme responsible for hydrogen peroxide detoxiﬁcation) activity,
whichwas prevented by the treatmentwith agmatine (Fig. 6B),without
causing signiﬁcant effects in the unstressed animals. A two-way ANOVA
revealed signiﬁcant effects of ARS [F(1,24) = 9.90, P b 0.01] and
ARS × treatment interaction [F(1,24) = 4.96, P b 0.05], but no sig-
niﬁcant main effect of treatment [F(1,24) = 2.90, P = 0.10]. Post
hoc analyses indicated that agmatine treatment abolished the alteration
in CAT and SOD activities induced byARS (P b 0.01). Of note, ARS caused
a huge increase in the hippocampal SOD/CAT ratio (Fig. 6C), which has
been pointed as an index of pro-oxidative conditions (Halliwell, 2007).
Agmatine prevented the ARS effects toward hippocampal SOD/CATFig. 3. Effect of the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) in the FST (panel A)
tistical analysis was performed by two-way ANOVA, followed by the Duncan's test. **P b 0.01 as
ARS-vehicle group.ratio (Fig. 6C). The two-way ANOVA revealed signiﬁcant differences of
ARS [F(1,28) = 16.00, P b 0.01], treatment [F(1,28) = 19.40, P b 0.01]
and ARS × treatment interaction [F(1,28) = 12.21, P b 0.01]. Post hoc
analyses indicated that agmatine treatment abolished the increase in
hippocampal SOD/CAT ratio caused by ARS (P b 0.01).
Finally, the effect of the treatment of ARS-mice with agmatine on
GPx and GR activities (important endogenous antioxidant enzymes)
was veriﬁed. ARS, but not vehicle or agmatine in unstressed mice, pro-
duced a slight increase in GPx activity (Fig. 7A). The two-way ANOVA
revealed a signiﬁcant effect of ARS [F(1,28) = 6.19, P b 0.05], but no
signiﬁcant main effects of treatment [F(1,28) = 0.004, P = 0.94] and
ARS × treatment interaction [F(1,28) = 0.72, P = 0.40]. Fig. 7B shows
that the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) was
able to prevent the increase on GR activity caused by the stress pro-
cedure. It is remarkable that agmatine treatment did not induce
these changes in unstressed animals. The two-way ANOVA revealed
signiﬁcant differences of ARS [F(1,28) = 9.81, P b 0.01], treatment
[F(1,28) = 6.44, P b 0.01] and ARS × treatment interaction [F(1,28) =
4.17, P b 0.05]. Post hoc analyses indicated that agmatine treatment
abolished the hippocampal increase on antioxidant activities of GPX
and GR caused by ARS (P b 0.01).
Worth of note is the positive Pearson's correlation (Table 1) among
immobility time and both TBARS (P b 0.05), GR (P b 0.05), and SOD
(P b 0.01). Also, a negative correlation was found between immobility
time and CAT (P b 0.01). It is interesting to note that a signiﬁcant corre-
lation was found between TBARS and GR (P b 0.05), and between GSH
with either GR (P b 0.05) or GPx (P b 0.05). A negative correlation wasand open-ﬁeld test (panel B). Each column represents the mean + S.E.M. (n = 7–8). Sta-
comparedwith the control group (unstressed-vehicle); ##P b 0.01 as comparedwith the
Fig. 4. Effect of the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) on thiobarbitu-
ric acid reactive substances (TBARS) in the hippocampus. Each column represents the
mean + S.E.M. (n = 7–8). Statistical analysis was performed by two-way ANOVA,
followed by the Duncan's test. **P b 0.01 as compared with the control group
(unstressed-vehicle); ##P b 0.01 as compared with the ARS-vehicle group.
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(P b 0.05). Number of crossings did not correlate with any variable
studied (data not shown).
4. Discussion
Agmatine has been proposed as a novel neuromodulator in the
central nervous system and is emerging as a novel candidate to assist
the conventional pharmacotherapy of depression. Previous ﬁndings
from our group have shown that agmatine administration by intra-
peritoneal (i.p.) and intracerebroventricular (i.c.v.) routes produces
antidepressant-like effect in the FST and TST (Zomkowski et al.,
2002, 2004, 2005). Nevertheless, in the present study we demon-
strated that an acute agmatine administration by oral route (p.o.)
produced a signiﬁcant antidepressant-like effect in the FST, a commonly
used behavioral test that predicts the efﬁcacy of antidepressant treat-
ment (Cryan and Holmes, 2005; Porsolt et al., 1977). Additionally, a
consistent antidepressant-like activity of agmatine in mice submitted
to the acute restrain stress, a procedure that has been extensively
shown to cause behavioral alterations indicative of depressive-like be-
havior (Kumar and Goyal, 2008; Poleszak et al., 2006; Zaﬁr et al.,
2009), was shown. The previous studies reporting antidepressant-like
effects of agmatine did not use animal models of depression. In this re-
gard, the results presented herein, which evince the agmatine's ability
to produce an antidepressant-like effect in a model of depressionFig. 5. Effect of the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) on glutathione
levels in the hippocampus. Each column represents themean + S.E.M. (n = 7–8). Statis-
tical analysis was performed by two-way ANOVA, followed by the Duncan's test.associated with an oxidative imbalance, represent a novelty on the
theme of antidepressant strategies.
The ARS has been proposed as a model of depression induced by
stress, which combines both emotional and physical components in ad-
dition to affect the brain's intra-cellular redox status (Buynitsky and
Mostofsky, 2009; Glavin et al., 1994; Paré and Glavin, 1986). The main
improvement of using restraint is that it produces an inescapable phys-
ical and mental stress which is not accompanied with a conditioned
response (Jaggi et al., 2011). It is relevant to clarify that this study was
performed in female mice because women are more susceptible to
development of depressive disorder followed to lifetime stress events
than men (Mazure and Maciejewski, 2003). Indeed, the ARS model of
depression standardized previously in our laboratory (Budni et al.,
2013; Moretti et al., 2013) was able to cause depressive-like behavior
associated with impairment in the in vivo antioxidant defenses, provid-
ing validation for themodel. Our results are in linewith this assumption,
since ARS caused emotional stress, evidenced by the depressive-related
behavior in the FST observed in animals submitted to this protocol. Of
note, agmatine administration by oral route (p.o.) was able to prevent
this behavioral alteration, reinforcing the antidepressant-like effect of
this neuromodulator.
It is well-known that the central nervous system is extremely sensi-
tive to peroxidative damage due to its rich content of oxidizable sub-
strates, high oxygen tension and low antioxidant capacity (Metodiewa
and Kośka, 2000; Zaﬁr et al., 2009). Several studies have shown that
stressful life events are associatedwith brain oxidative damage as a con-
sequence of an increase in the production of ROS, such as superoxide
anion radical (O2•−), hydroxyl radical (HO•), and hydrogen peroxide
(H2O2) (Anisman et al., 2002; Leonard and Maes, 2012; Maes et al.,
2009). The endogenous detoxiﬁcation system involves the activity of
several antioxidant enzymes. SOD, is the ﬁrst line of defense against
ROS and catalyzes the dismutation of superoxide anion radical into hy-
drogen peroxide (Singh, 1982). The H2O2 produced from O2•− can be
reduced to water and molecular oxygen by either catalase (CAT) (Del
Río et al., 1992) or glutathione peroxidase (GPx) (Brigelius-Flohé,
1999). The H2O2 detoxiﬁcation mediated by GPx expends reduced glu-
tathione (GSH), which in turn is oxidized producing glutathione disul-
ﬁde (GSSG) (Flohé, 1971). The GSSG produced in GPx mediated
reaction can be restored to GSH through a reaction catalyzed by gluta-
thione reductase (GR), at the expense of the reducing equivalents
from NADPH (Kirsch and De Groot, 2001).
Lipid peroxidation is considered a critical mechanism of injury oc-
curring in cells during oxidative stress (Halliwell and Gutteridge,
1999; Niki, 2012). An initial formation of large amounts of ROS during
stress may also initiate lipid peroxidation as demonstrated to occur in
brain (Hayashi et al., 2012). Emotional stress, which accompanies
severe depression, may enhance lipid peroxidation (Goncharova et al.,
2008) and clinical studies have directly demonstrated higher levels of
MDA—an end-product of lipid peroxidation, in patients with affective
disorders (Lang and Borgwardt, 2013; Ozcan et al., 2004). In addition,
several studies have demonstrated that the restrained stress signiﬁcant-
ly elevated lipid peroxidation level in the hippocampus of rats (Abidin
et al., 2004; Atif et al., 2008; de Balk et al., 2010; Fontella et al., 2005)
and mice (Budni et al., 2013; García-Fernández et al., 2012; Moretti
et al., 2013; Perez Nievas et al., 2011). In line with this, our results
show that the ARS procedure caused a signiﬁcant lipid peroxidation,
as evidenced by increased amount of TBARS levels in ARS-mice, which
was abolished by agmatine treatment. Thus, the beneﬁcial effects of
agmatine on behavior could be associated with its capacity to prevent
the lipid peroxidative damage caused by immobilization stress. This hy-
pothesis is supported by the positive correlation among immobility
time and TBARS results.
The glutathione (GSH) system is an important tool mediating
protection against several (pro)-oxidant molecules in the brain
(Dringen and Hirrlinger, 2003) and alterations is this system are in-
volved in several neuropathological conditions (Lovell et al., 1998). A
Fig. 6. Effect of the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) on SOD activity (panel A), on CAT activity (panel B) and on SOD/CAT ratio in the hippocampus (panel C). Each
column represents the mean + S.E.M. (n = 7–8). Statistical analysis was performed by two-way ANOVA, followed by the Duncan's test. **P b 0.01 as compared with the control group
(unstressed-vehicle); ##P b 0.01 as compared with the ARS-vehicle group.
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tration of GSH elicits an antidepressant-like response in the FST and
TST inmice. Recent studies performed by Budni et al. (2013), Moretti
et al. (2013) and Méndez-Cuesta et al. (2011), however, reported
that restraint stress in rodents did not affect GSH levels in the brain.
The present study is in agreement with these ﬁndings, since neither
agmatine nor ARS caused alterations in GSH levels in the hippocampus
of mice, suggesting that this molecular target is not directly underlyingFig. 7. Effect of the treatment of ARS-mice with agmatine (10 mg/kg, p.o.) on GPx activity (
mean + S.E.M. (n = 7–8). Statistical analysis was performed by two-way ANOVA, fo
group (unstressed-vehicle); ##P b 0.01 as compared with the ARS-vehicle group.the antidepressant effect of agmatine in ARS-mice. Nevertheless,
considering that a positive correlation among GSH results and both
GR and GPx was shown, it could be speculated that GSH is somehow
involved in the maintenance of pro/anti-oxidative homeostasis of
ARS-mice hippocampus.
In the present study, we identiﬁed a signiﬁcant imbalance in SOD,
GPx, GR and CAT hippocampal activities after ARS procedure. Indeed,
Sarandol et al. (2007) have demonstrated that patients suffering frompanel A) and on GR activity (panel B) in the hippocampus. Each column represents the
llowed by the Duncan's test. *P b 0.05, **P b 0.01 as compared with the control
Table 1
Pearson's correlation among selected variables.
Measures Immobility time TBARS GSH GR GPx
TBARS 0.43*
GSH 0.03 0.11
GR 0.40* 0.45** 0.37*
GPx −0.02 0.21 0.40* 0.30
CAT −0.45** −0.33 −0.23 −0.36* −0.16
SOD 0.50** 0.29 0.17 0.30 0.35*
Signiﬁcant at *P b 0.05 or **P b 0.01.
149A.E. Freitas et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 50 (2014) 143–150major depressive disorder (MDD) presented higher MDA levels and
SOD activity, as compared to the control group. In addition, this
study found a signiﬁcant positive correlation among the severity of
the disease and SOD activity. Similarly, Kotan et al. (2011) demon-
strated that patients who fully met the fourth Diagnostic and Statis-
tical Manual ofMental Disorder criteria forMDD presented increased
levels of MDA and SOD activity. Furthermore, it was also demonstrat-
ed that MDD patients presented higher levels of plasma GR and MDA
levels, and erythrocyte GPx and SOD than those of control (Bilici
et al., 2001). Increased GR activity was further found in depressive
women (Kodydková et al., 2009). Finally, Ozcan et al. (2004) have
shown a lower CAT activity inMDDpatients. The present results concur
with these clinical evidence since the ARS-mice presented a depressive-
like behavior accompanied by increased lipid peroxidation, SOD, GPx,
GR activities and a lower activity of CAT in the hippocampus. Consider-
ing the pre-clinical studies, several authors have shown similar
increased lipid peroxidation, SOD, GPx, and GR activities induced by im-
mobilization stress in the hippocampus (Budni et al., 2013; de Balk
et al., 2010; Fontella et al., 2005; García-Fernández et al., 2012;
Moretti et al., 2013). Additionally, a lower activity of brain CAT caused
by immobilization stress was also shown (Akpinar et al., 2008; Derin
et al., 2006; Enache et al., 2008; Kumar et al., 2009). Further supporting
this notion, a positive correlation was found among immobility time
and both TBARS, GR, and SOD. In addition, TBARS correlates with GR,
and GSH with both GR and GPx. Besides, a signiﬁcant correlation be-
tween SOD and GPx was found. Finally, CAT correlates negatively with
bothGR and immobility time. Altogether, these results indicate a poten-
tial relationship among the several oxidative stress-related parameters
in the hippocampus of animals subjected to ARS. Of note, ARS caused a
signiﬁcant increase in the hippocampal SOD/CAT ratio, which has been
pointed as an index of pro-oxidative conditions; it favors the higher
levels of hydrogen peroxide because SOD converts superoxide anion
to hydrogen peroxide, but CAT is not able to metabolize hydrogen per-
oxide to water (Halliwell, 2007). In this context, the signiﬁcant increase
in hippocampal GR activity in ARS group might represent a potential
secondary response to prevent ARS-induced pro-oxidative damage, as
already observed in other studies (Budni et al., 2013; Farina et al.,
2005). However, this responsewas not enough to prevent hippocampal
oxidative damage, evidenced by the increased lipid peroxidation rate in
animals from the ARS group. Of note, agmatine, which abolished ARS-
induced changes on CAT and SOD activities, also prevented the in-
creases in GR activity and lipid peroxidation, strongly reinforcing the
potential relationship among the evaluated biochemical parameters.
5. Conclusion
The present study extends literature data by indicating some
possible mechanisms underlying the antidepressant-like effect of
agmatine in a model of depression induced by restraint stress. ARS
induced a signiﬁcant lipid peroxidation and alterations in the activity
of the enzymes SOD, GPx, GR, CAT and in the SOD/CAT ratio in the
hippocampus, indicating an oxidative imbalance. Furthermore,
agmatine administered acutely by oral route produced a signiﬁcant
antidepressant-like effect in the FST and was effective to prevent
the behavioral alterations induced by ARS. These effects of agmatineseem to be associated with a modulation of TBARS, SOD, GR, and CAT,
but not directly with GSH and GPx. The role of each of these targets
deserves further studies to determine their direct relation to the an-
tidepressant action of agmatine. Nevertheless, the present study
delves into one of the pleiotropic effects of agmatine by highlighting
that its antidepressant-like effect in the ARS model of depression is,
at least in part, accompanied by its capability of maintaining pro-/
anti-oxidant homeostasis in the hippocampus.
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